Why Boundless Bio, Inc.’s (BOLD) Stock Is Up 5.69%
As of Wednesday, August 05, Boundless Bio, Inc.’s BOLD share price has surged by 5.69%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Commentary & Analysis
Why Boundless Bio, Inc.’s (BOLD) Stock Is Up 7.35%
As of Tuesday, June 30, Boundless Bio, Inc.’s BOLD share price has surged by 7.35%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | BOLD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $65.7 | $282.5 | 17% |
|
| Shares Out (Mil) | 22.5 | 54.1 | 32% |
|
| Institutional Ownership | 96.8% | 92.9% | 71% |
|
| Float (Mil) | 16.1 | 41.5 | 26% |
|
| Beta | 0.38 | 0.94 | 22% |
|
| Avg Daily Volume (000s) | 116 | 469 | 38% |
|
| Price Change (52-week) |
158.0% | 59.1% | 96% |
|
| Growth | BOLD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.560) | ($2.530) | ($0.980) | |
| Month Ago EPS | ($0.610) | ($2.400) | ($0.930) | |
| # Rev Up | 0 | 2 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($0.633) | ($2.380) | ($1.280) | |
| Year/Year Chg | (46.9%) | (2.8%) | na | |
| Financials | BOLD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($64) | ($43) | 14% |
|
| EPS (TTM) | ($2.856) | ($1.500) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($56) | ($31) | 9% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($9) | $195 | 2% |
|
| Valuation | BOLD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.98 | 2.78 | 21% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BOLD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (50.6%) | (47.6%) | 11% |
|
| ROE | (67.9%) | (55.0%) | 12% |
|
| Liabilities to Assets | 10.5% | 29.6% | 6% |
|
| F-Score | 2 | 3 | 7% |
|
Boundless Bio, Inc. did not pass any screens on 9/1/2026.
